drugset
drugset / Trial / NCT02036489

Pethema LAL-RI/2008: Treatment for Patients With Standard Risk Acute Lymphoblastic Leukemia

NCT02036489 ↗

Phase 4 Completed 107 enrolled PETHEMA Foundation
Non-randomizedSingle-groupOpen-labelTreatment

Summary

Understand the dynamics of elimination of MRD in adult patients with standard-risk LAL treated with a pediatric protocol.

Timeline

Start
2008-01
Primary completion
2019-12-01
Completion
2019-12-01

Drugs

EvaluationDrugModalityDoseRoute
Subject CYCLOPHOSPHAMIDE ANHYDROUS Small molecule 600 mg/m2 Intravenous
Subject CYCLOPHOSPHAMIDE ANHYDROUS Small molecule 1000 mg/m2 Intravenous
Subject Cytarabine Small molecule 30 mg Intrathecal
Subject Cytarabine Small molecule 500 mg/m2 Intrathecal
Subject Daunorubicin Small molecule 30 mg/m2 Intravenous
Subject Dexamethasone Small molecule 10 mg/m2 Oral
Subject Etoposide Small molecule 100 mg/m2 —
Subject Hidrocortisone Unknown 20 mg Intrathecal
Subject MERCAPTOPURINE ANHYDROUS Small molecule 50 mg/m2 Oral
Subject Metotrexate Unknown 12 mg Intrathecal
Subject Metotrexate Unknown 20 mg/m2 Intrathecal
Subject Metotrexate Unknown 3 g Intrathecal
Subject Prednisone Other / unclassified 60 mg/m2 Oral
Subject Vincristine Small molecule 1.5 mg/m2 Intravenous
Subject asparaginase Protein / enzyme biologic 10000 iu Intravenous

Indications

acute lymphoblastic leukemia